Here’s the latest development on Pharmaxis’ (ASX:PXS) cancer treatment

  • February 22, 2021 12:25 PM AEDT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2781 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Here’s the latest development on Pharmaxis’ (ASX:PXS) cancer treatment

Summary

  • ASX-listed Pharmaxis has enrolled the first patient for the clinical trial to evaluate a potential new treatment for bone marrow cancer.
  • The study also includes a dose-escalation phase to select an optimum dose of PXS-5505.
  • PXS-5505 also has potential in several other cancers, including liver and pancreatic cancer.
Gold MTF non-AMP

Australian pharmaceutical research player Pharmaxis Ltd (ASX:PXS) has announced that it has enrolled the first patient for the clinical trial of PXS-5505 to determine the safety profile in patients with myelofibrosis.

Source: © Arturszczybylo| Megapixl.com

Let us dive deeper and discuss the study in detail-

PXS-5505 study in myelofibrosis

On 22 February 2021, Pharmaxis disclosed that the first patient for the trial to study a potential new treatment for bone marrow cancer myelofibrosis had been enrolled.  The trial’s primary endpoint is to determine the safety of PXS-5505, Pharmaxis’ lead asset in its pipeline, in patients with myelofibrosis.

The Company disclosed that the phase 1c/2a trial aims to demonstrate that PXS-5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive, or ineligible for treatment with approved JAK inhibitor drugs. The trial was approved by the Food and Drug Administration (FDA) under the Investigational New Drug (IND) scheme.

Pharmaxis has completed site initiation at several hospitals in Australia and South Korea, and the first patient for the study has been enrolled.

The dose-escalation phase intends to select an optimum dose of PXS-5505.  This first phase will recruit up to 18 patients and is anticipated to conclude and report in the second half of 2021. This phase will be followed by a dose-expansion phase for six-month in 24 patients to evaluate the safety and efficacy.

Pharmaxis updated the market that the clinical investigation sites in other countries, including the US, will be added for the dose-expansion phase.

ALSO READ: Pharmaxis (ASX:PXS) exports the first shipment of Bronchitol® to the US

Secondary endpoints of the study

The secondary endpoints of the study are-

PXS-5505 in a nutshell

  • PXS-5505 is an orally administered drug that inhibits the lysyl oxidase family of enzymes.
  • In pre-clinical studies of myelofibrosis, PXS-5505 administration reversed the bone marrow fibrosis that drives morbidity as well as mortality in myelofibrosis.
  • PXS-5505 also reduced many abnormalities which are associated with this disease.

Gary Phillips, CEO of Pharmaxis, commented-

The Company highlighted that while its primary focus is developing PXS-5505 for myelofibrosis, the drug has the potential to treat several other cancers, including liver and pancreatic cancer. In these cancers, PXS-5505 intends to breakdown the fibrotic tissue in the tumour and improve the effect of chemotherapy treatment.

Stock Information: At AEDT 12:14 PM, PXS shares were trading at A$0.086, up 1.176% compared to the previous close. The Company has a market capitalisation of A$33.76 million.

DO READ: Pharmaxis Ltd (ASX:PXS) Obtains Milestone Payment from Chiesi Post FDA Approval

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK